首页 > 最新文献

Journal of nuclear medicine technology最新文献

英文 中文
18F-Fluoroestradiol Whole-Body Imaging. 18F氟雌二醇全身成像。
IF 1.3 Q2 Medicine Pub Date : 2023-09-01 DOI: 10.2967/jnmt.122.265271
Barbara J Grabher
{"title":"<sup>18</sup>F-Fluoroestradiol Whole-Body Imaging.","authors":"Barbara J Grabher","doi":"10.2967/jnmt.122.265271","DOIUrl":"10.2967/jnmt.122.265271","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FES Whole-Body Imaging Protocol for Evaluating Tumor Estrogen Receptor Status in Patients with Recurrent or Metastatic Breast Cancer. 用于评估复发性或转移性乳腺癌患者肿瘤雌激素受体状态的 18F-FES 全身成像方案。
IF 1.3 Q2 Medicine Pub Date : 2023-09-01 Epub Date: 2023-07-11 DOI: 10.2967/jnmt.122.265272
Barbara J Grabher

In September 2020, the Journal of Nuclear Medicine and Technology published a continuing education article, "Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes," that reviewed a promising new PET tracer, 16α-18F-fluoro-17β-fluoroestradiol (18F-FES). This tracer had the potential to be a valuable tool for medical oncologists and breast surgeons in noninvasively evaluating the estrogen receptor site status of their patients' recurrent tumor and secondary metastatic lesions. In May 2020, 18F-FES received Food and Drug Administration approval and began being marketed by Zionexa using the trade name Cerianna and manufactured by PETNET. In May 2021, GE Healthcare acquired Zionexa, and Cerianna and is now being marketed by GE Healthcare and is still being manufactured by PETNET. This article will review the 18F-FES package insert information and imaging protocol, as well as important guidelines for imaging with 18F-FES.

2020 年 9 月,《核医学与技术杂志》发表了一篇题为 "乳腺癌:通过分子成像评估肿瘤雌激素受体状态以提高治疗反应并改善患者预后》一文,回顾了一种前景广阔的新型 PET 示踪剂 16α-18F-氟-17β-氟雌二醇(18F-FES)。这种示踪剂有望成为肿瘤内科医生和乳腺外科医生无创评估患者复发肿瘤和继发性转移病灶的雌激素受体部位状态的重要工具。2020 年 5 月,18F-FES 获得了美国食品药品管理局的批准,并开始由 Zionexa 公司销售,商品名为 Cerianna,由 PETNET 公司生产。2021 年 5 月,通用电气医疗集团收购了 Zionexa 和 Cerianna,目前由通用电气医疗集团销售,仍由 PETNET 生产。本文将回顾 18F-FES 包装插页信息和成像协议,以及使用 18F-FES 进行成像的重要指南。
{"title":"<sup>18</sup>F-FES Whole-Body Imaging Protocol for Evaluating Tumor Estrogen Receptor Status in Patients with Recurrent or Metastatic Breast Cancer.","authors":"Barbara J Grabher","doi":"10.2967/jnmt.122.265272","DOIUrl":"10.2967/jnmt.122.265272","url":null,"abstract":"<p><p>In September 2020, the <i>Journal of Nuclear Medicine and Technology</i> published a continuing education article, \"Breast Cancer: Evaluating Tumor Estrogen Receptor Status with Molecular Imaging to Increase Response to Therapy and Improve Patient Outcomes,\" that reviewed a promising new PET tracer, 16α-<sup>18</sup>F-fluoro-17β-fluoroestradiol (<sup>18</sup>F-FES). This tracer had the potential to be a valuable tool for medical oncologists and breast surgeons in noninvasively evaluating the estrogen receptor site status of their patients' recurrent tumor and secondary metastatic lesions. In May 2020, <sup>18</sup>F-FES received Food and Drug Administration approval and began being marketed by Zionexa using the trade name Cerianna and manufactured by PETNET. In May 2021, GE Healthcare acquired Zionexa, and Cerianna and is now being marketed by GE Healthcare and is still being manufactured by PETNET. This article will review the <sup>18</sup>F-FES package insert information and imaging protocol, as well as important guidelines for imaging with <sup>18</sup>F-FES.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10538239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Conversation with ChatGPT. 与 ChatGPT 对话。
IF 1.3 Q2 Medicine Pub Date : 2023-09-01 Epub Date: 2023-07-11 DOI: 10.2967/jnmt.123.265864
Geoffrey Currie

ChatGPT chatbot powered by GPT 3.5 was released in late November 2022 but has been rapidly assimilated into educational and clinical environments. Method: Insight into ChatGPT capabilities was undertaken in an interview-style approach with the chatbot itself. Results: ChatGPT powered by GPT 3.5 exudes confidence in its capabilities in supporting and enhancing student learning in nuclear medicine and in supporting clinical practice. ChatGPT is also self-aware of limitations and flaws in capabilities and the risks these pose to academic integrity. Conclusion: Further objective evaluation of ChatGPT capabilities in authentic learning and clinical scenarios is required.

由 GPT 3.5 支持的 ChatGPT 聊天机器人于 2022 年 11 月底发布,但已迅速融入教育和临床环境。方法:通过对聊天机器人本身进行访谈,深入了解 ChatGPT 的功能。结果由 GPT 3.5 支持的 ChatGPT 在支持和提高学生核医学学习能力以及支持临床实践方面表现出了自信。ChatGPT 也意识到自身能力的局限性和缺陷,以及这些能力给学术诚信带来的风险。结论:需要进一步客观评估 ChatGPT 在真实学习和临床场景中的能力。
{"title":"A Conversation with ChatGPT.","authors":"Geoffrey Currie","doi":"10.2967/jnmt.123.265864","DOIUrl":"10.2967/jnmt.123.265864","url":null,"abstract":"<p><p>ChatGPT chatbot powered by GPT 3.5 was released in late November 2022 but has been rapidly assimilated into educational and clinical environments. <b>Method:</b> Insight into ChatGPT capabilities was undertaken in an interview-style approach with the chatbot itself. <b>Results:</b> ChatGPT powered by GPT 3.5 exudes confidence in its capabilities in supporting and enhancing student learning in nuclear medicine and in supporting clinical practice. ChatGPT is also self-aware of limitations and flaws in capabilities and the risks these pose to academic integrity. <b>Conclusion:</b> Further objective evaluation of ChatGPT capabilities in authentic learning and clinical scenarios is required.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10538238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ChatGPT in Nuclear Medicine Education. 核医学教育中的 ChatGPT。
IF 1.3 Q2 Medicine Pub Date : 2023-09-01 Epub Date: 2023-07-11 DOI: 10.2967/jnmt.123.265844
Geoffrey Currie, Kym Barry

Academic integrity has been challenged by artificial intelligence algorithms in teaching institutions, including those providing nuclear medicine training. The GPT 3.5-powered ChatGPT chatbot released in late November 2022 has emerged as an immediate threat to academic and scientific writing. Methods: Both examinations and written assignments for nuclear medicine courses were tested using ChatGPT. Included was a mix of core theory subjects offered in the second and third years of the nuclear medicine science course. Long-answer-style questions (8 subjects) and calculation-style questions (2 subjects) were included for examinations. ChatGPT was also used to produce responses to authentic writing tasks (6 subjects). ChatGPT responses were evaluated by Turnitin plagiarism-detection software for similarity and artificial intelligence scores, scored against standardized rubrics, and compared with the mean performance of student cohorts. Results: ChatGPT powered by GPT 3.5 performed poorly in the 2 calculation examinations (overall, 31.7% compared with 67.3% for students), with particularly poor performance in complex-style questions. ChatGPT failed each of 6 written tasks (overall, 38.9% compared with 67.2% for students), with worsening performance corresponding to increasing writing and research expectations in the third year. In the 8 examinations, ChatGPT performed better than students for general or early subjects but poorly for advanced and specific subjects (overall, 51% compared with 57.4% for students). Conclusion: Although ChatGPT poses a risk to academic integrity, its usefulness as a cheating tool can be constrained by higher-order taxonomies. Unfortunately, the constraints to higher-order learning and skill development also undermine potential applications of ChatGPT for enhancing learning. There are several potential applications of ChatGPT for teaching nuclear medicine students.

教学机构(包括提供核医学培训的机构)中的人工智能算法对学术诚信提出了挑战。2022 年 11 月底发布的由 GPT 3.5 驱动的 ChatGPT 聊天机器人已成为学术和科学写作的直接威胁。方法:使用 ChatGPT 测试了核医学课程的考试和书面作业。其中包括核医学科学课程第二年和第三年的核心理论科目。考试包括长答题(8 个科目)和计算题(2 个科目)。ChatGPT 还被用于制作真实写作任务的回复(6 个科目)。通过 Turnitin 抄袭检测软件对 ChatGPT 作答的相似度和人工智能评分进行评估,根据标准化评分标准进行评分,并与同组学生的平均成绩进行比较。结果由 GPT 3.5 支持的 ChatGPT 在两次计算考试中表现不佳(总成绩为 31.7%,而学生成绩为 67.3%),尤其是在复杂题型中表现不佳。ChatGPT 在 6 项书面任务中均不及格(总体不及格率为 38.9%,而学生不及格率为 67.2%),随着第三学年对写作和研究的要求不断提高,其表现也越来越差。在 8 次考试中,ChatGPT 在一般科目或早期科目中的表现优于学生,但在高级科目和特殊科目中的表现较差(总体而言,51%,而学生为 57.4%)。结论:虽然 ChatGPT 对学术诚信构成风险,但其作为作弊工具的实用性会受到高阶分类标准的限制。不幸的是,对高阶学习和技能发展的限制也削弱了 ChatGPT 在促进学习方面的潜在应用。ChatGPT 在核医学学生教学方面有几种潜在的应用。
{"title":"ChatGPT in Nuclear Medicine Education.","authors":"Geoffrey Currie, Kym Barry","doi":"10.2967/jnmt.123.265844","DOIUrl":"10.2967/jnmt.123.265844","url":null,"abstract":"<p><p>Academic integrity has been challenged by artificial intelligence algorithms in teaching institutions, including those providing nuclear medicine training. The GPT 3.5-powered ChatGPT chatbot released in late November 2022 has emerged as an immediate threat to academic and scientific writing. <b>Methods:</b> Both examinations and written assignments for nuclear medicine courses were tested using ChatGPT. Included was a mix of core theory subjects offered in the second and third years of the nuclear medicine science course. Long-answer-style questions (8 subjects) and calculation-style questions (2 subjects) were included for examinations. ChatGPT was also used to produce responses to authentic writing tasks (6 subjects). ChatGPT responses were evaluated by Turnitin plagiarism-detection software for similarity and artificial intelligence scores, scored against standardized rubrics, and compared with the mean performance of student cohorts. <b>Results:</b> ChatGPT powered by GPT 3.5 performed poorly in the 2 calculation examinations (overall, 31.7% compared with 67.3% for students), with particularly poor performance in complex-style questions. ChatGPT failed each of 6 written tasks (overall, 38.9% compared with 67.2% for students), with worsening performance corresponding to increasing writing and research expectations in the third year. In the 8 examinations, ChatGPT performed better than students for general or early subjects but poorly for advanced and specific subjects (overall, 51% compared with 57.4% for students). <b>Conclusion:</b> Although ChatGPT poses a risk to academic integrity, its usefulness as a cheating tool can be constrained by higher-order taxonomies. Unfortunately, the constraints to higher-order learning and skill development also undermine potential applications of ChatGPT for enhancing learning. There are several potential applications of ChatGPT for teaching nuclear medicine students.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10538242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Gathering. 收集。
IF 1.3 Q2 Medicine Pub Date : 2023-09-01
Kathy S Thomas
{"title":"The Gathering.","authors":"Kathy S Thomas","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10159722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Duration of Breastfeeding Interruption in Nuclear Medicine Procedures. 核医学程序中母乳喂养中断的持续时间。
IF 1.3 Q2 Medicine Pub Date : 2023-09-01 DOI: 10.2967/jnmt.122.264910
Dhrumil Naik, Hema Merai, Ran Klein, Wanzhen Zeng

The recommendation for the duration of breastfeeding interruption after radiopharmaceutical administration has not been standardized and varies among the guidance documents and publications in the literature. Methods: A working group consisting of 3 staff physicians, 2 fellows, and 2 technologists was designated to update the institutional recommendations on breastfeeding interruption based on the review of the guidance documents and the literature. Results: Our institutional recommendations on the duration of breastfeeding interruption for 54 radiopharmaceuticals are presented in 4 summary tables. For completeness, we also include other radiopharmaceuticals with available information. Conclusion: The detailed recommendation summary on breastfeeding might be helpful to other centers.

关于服用放射性药物后母乳喂养中断时间的建议尚未标准化,并且在不同的指导文件和文献出版物中各不相同。方法:指定一个由3名主治医师、2名研究员和2名技术人员组成的工作组,在审查指导文件和文献的基础上更新有关母乳喂养中断的机构建议。结果:我们对54种放射性药物的母乳喂养中断时间的机构建议分为4个汇总表。为完整起见,我们还包括其他具有可用信息的放射性药物。结论:详细的母乳喂养建议总结可能对其他中心有所帮助。
{"title":"Duration of Breastfeeding Interruption in Nuclear Medicine Procedures.","authors":"Dhrumil Naik,&nbsp;Hema Merai,&nbsp;Ran Klein,&nbsp;Wanzhen Zeng","doi":"10.2967/jnmt.122.264910","DOIUrl":"https://doi.org/10.2967/jnmt.122.264910","url":null,"abstract":"<p><p>The recommendation for the duration of breastfeeding interruption after radiopharmaceutical administration has not been standardized and varies among the guidance documents and publications in the literature. <b>Methods:</b> A working group consisting of 3 staff physicians, 2 fellows, and 2 technologists was designated to update the institutional recommendations on breastfeeding interruption based on the review of the guidance documents and the literature. <b>Results:</b> Our institutional recommendations on the duration of breastfeeding interruption for 54 radiopharmaceuticals are presented in 4 summary tables. For completeness, we also include other radiopharmaceuticals with available information. <b>Conclusion:</b> The detailed recommendation summary on breastfeeding might be helpful to other centers.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10166047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States. 针对前列腺特异性膜抗原的抗体J591的α-标记:来自美国某学术机构第一个专门生产实验室的技术和考虑
IF 1.3 Q2 Medicine Pub Date : 2023-09-01 DOI: 10.2967/jnmt.122.265166
Kritika Subramanian, Judith Stangl-Kremser, Lady Sawoszczyk, Vasilios Avlonitis, Andrew Gernerd, Kyla Nixon, Michael Zgaljardic, Scott Tagawa, Neil Bander, Joseph R Osborne

The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop 225Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent.

前列腺特异性膜抗原的蛋白表达与前列腺癌的不利或侵袭性组织学特征相关,因此被用作诊断性PET成像放射性示踪剂和治疗靶点。在此,我们讨论了开发225Ac-DOTA-J591的方法,这是一种α-标记的靶向前列腺特异性膜抗原细胞外表位的化合物,目前正在进行早期临床试验研究。此外,我们回顾了质量控制,辐射安全措施,以及在使用这种放射免疫治疗剂之前的临床考虑。
{"title":"α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States.","authors":"Kritika Subramanian,&nbsp;Judith Stangl-Kremser,&nbsp;Lady Sawoszczyk,&nbsp;Vasilios Avlonitis,&nbsp;Andrew Gernerd,&nbsp;Kyla Nixon,&nbsp;Michael Zgaljardic,&nbsp;Scott Tagawa,&nbsp;Neil Bander,&nbsp;Joseph R Osborne","doi":"10.2967/jnmt.122.265166","DOIUrl":"https://doi.org/10.2967/jnmt.122.265166","url":null,"abstract":"<p><p>The protein expression of the prostate-specific membrane antigen correlates with unfavorable or aggressive histologic features of prostate cancer, resulting in use as a diagnostic PET imaging radiotracer and therapeutic target. Here, we discuss the methods to develop <sup>225</sup>Ac-DOTA-J591, an α-labeled compound targeting an extracellular epitope of prostate-specific membrane antigen, which is currently being studied in early clinical trials. In addition, we review quality control, radiation safety measures, and clinical considerations before administration of this radioimmunotherapeutic agent.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10166048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Effectiveness of Ionized Water as a Radiodecontaminant for 99mTc-Pertechnetate and 131I. 离子水作为放射性污染物对99mtc -高锝酸盐和131I的有效性。
IF 1.3 Q2 Medicine Pub Date : 2023-09-01 DOI: 10.2967/jnmt.122.265150
Mary Angeline P Rillorta, Allan Jay Espiritu

Immediate and complete decontamination procedures are essential to restore the functionality, precision, accuracy, and safety of tests done within the nuclear medicine facility. Decontamination is a simple procedure that, if performed correctly, effectively reduces exposure brought about by spills. The determination of a suitable radiodecontaminant may be beneficial in decontaminating patient beds, collimators, probes, and machines. Methods: Two surface types (i.e., stainless steel and vinyl) were contaminated with a predetermined activity of 99mTcO4 and 131I. After air drying, static images of the contaminated surfaces were obtained using a γ-camera to determine the activity counts on each surface before and after decontamination procedures. Different decontaminant contact times (i.e., 5, 10, and 15 min) were used for each decontaminant (i.e., ionized water, 10% bleach, detergent solution, a negative control [no treatment], and a positive control [a commercial radiodecontaminant]). Differences between the effectiveness of ionized water and the other decontaminants against 99mTcO4 and 131I at different contact times were measured, and the mean percentage activity removed (%AR) was compared using 2-way ANOVA at the 0.05 level of significance. Results: 99mTcO4 and 131I contaminants had %ARs of greater than 80% after 5 min of contact time for ionized water and the other decontaminants. At 15 min contact time, ionized water was not as effective as the other decontaminating agents for 131I on vinyl surfaces. There was no significant interaction between the effects of the decontaminants (%AR) and the contact times with stainless steel and vinyl for either 99mTcO4 or 131I. Conclusion: For 99mTcO4 and 131I on stainless steel surfaces, ionized water is an effective decontaminant at contact times of 5, 10, and 15 min. For 99mTcO4 on vinyl surfaces, ionized water is also an effective decontaminant at contact times of 5, 10, and 15 min. For 131I on vinyl surfaces, ionized water is as effective as 10% bleach, detergent solution, and a commercial radiodecontaminant at contact times of 5 and 10 min.

立即和完整的去污程序对于恢复在核医学设施内进行的试验的功能、精度、准确性和安全性至关重要。净化是一个简单的程序,如果操作正确,可以有效地减少泄漏带来的暴露。确定合适的放射性去污剂对病床、准直器、探针和机器的去污是有益的。方法:以99mTcO4和131I的预定活性污染两种表面类型(即不锈钢和乙烯基)。空气干燥后,使用γ-照相机获得污染表面的静态图像,以确定净化程序前后每个表面的活性计数。每种去污剂(即离子水、10%漂白剂、洗涤剂溶液、阴性对照[未处理]和阳性对照[商用放射性去污剂])使用不同的去污接触时间(即5、10和15分钟)。测量了不同接触时间离子水和其他去污剂对99mTcO4和131I的有效性差异,并使用2-way方差分析在0.05显著水平上比较平均去除活性百分比(%AR)。结果:99mTcO4和131I污染物与离子水和其他去污剂接触5 min后,% ar值大于80%。在接触时间为15 min时,离子水对乙烯基表面131I的去除率不如其他去污剂。对于99mTcO4或131I,去污剂(%AR)的效果与不锈钢和乙烯基的接触次数之间没有显著的相互作用。结论:对于不锈钢表面的99mTcO4和131I,离子水在接触5、10和15分钟时是有效的去污剂。对于乙烯基表面的99mTcO4,离子水在接触5、10和15分钟时也是有效的去污剂。对于乙烯基表面的131I,离子水在接触5和10分钟时与10%漂白剂、洗涤剂溶液和商业放射性去污剂一样有效。
{"title":"The Effectiveness of Ionized Water as a Radiodecontaminant for <sup>99m</sup>Tc-Pertechnetate and <sup>131</sup>I.","authors":"Mary Angeline P Rillorta,&nbsp;Allan Jay Espiritu","doi":"10.2967/jnmt.122.265150","DOIUrl":"https://doi.org/10.2967/jnmt.122.265150","url":null,"abstract":"<p><p>Immediate and complete decontamination procedures are essential to restore the functionality, precision, accuracy, and safety of tests done within the nuclear medicine facility. Decontamination is a simple procedure that, if performed correctly, effectively reduces exposure brought about by spills. The determination of a suitable radiodecontaminant may be beneficial in decontaminating patient beds, collimators, probes, and machines. <b>Methods:</b> Two surface types (i.e., stainless steel and vinyl) were contaminated with a predetermined activity of <sup>99m</sup>TcO<sub>4</sub> and <sup>131</sup>I. After air drying, static images of the contaminated surfaces were obtained using a γ-camera to determine the activity counts on each surface before and after decontamination procedures. Different decontaminant contact times (i.e., 5, 10, and 15 min) were used for each decontaminant (i.e., ionized water, 10% bleach, detergent solution, a negative control [no treatment], and a positive control [a commercial radiodecontaminant]). Differences between the effectiveness of ionized water and the other decontaminants against <sup>99m</sup>TcO<sub>4</sub> and <sup>131</sup>I at different contact times were measured, and the mean percentage activity removed (%AR) was compared using 2-way ANOVA at the 0.05 level of significance. <b>Results:</b> <sup>99m</sup>TcO<sub>4</sub> and <sup>131</sup>I contaminants had %ARs of greater than 80% after 5 min of contact time for ionized water and the other decontaminants. At 15 min contact time, ionized water was not as effective as the other decontaminating agents for <sup>131</sup>I on vinyl surfaces. There was no significant interaction between the effects of the decontaminants (%AR) and the contact times with stainless steel and vinyl for either <sup>99m</sup>TcO<sub>4</sub> or <sup>131</sup>I. <b>Conclusion:</b> For <sup>99m</sup>TcO<sub>4</sub> and <sup>131</sup>I on stainless steel surfaces, ionized water is an effective decontaminant at contact times of 5, 10, and 15 min. For <sup>99m</sup>TcO<sub>4</sub> on vinyl surfaces, ionized water is also an effective decontaminant at contact times of 5, 10, and 15 min. For <sup>131</sup>I on vinyl surfaces, ionized water is as effective as 10% bleach, detergent solution, and a commercial radiodecontaminant at contact times of 5 and 10 min.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10166049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Investigating a Technologist-Driven Injection Technique in Lymphoscintigraphy at a Single Rural Center: A Retrospective Audit. 在单个农村中心调查技术驱动的淋巴显像注射技术:回顾性审计。
IF 1.3 Q2 Medicine Pub Date : 2023-09-01 DOI: 10.2967/jnmt.123.265442
Skyla Bamforth, Daphne J James, Christopher Skilton, Anthony Smith

Our aim was to investigate the effectiveness of the technologist-driven injection technique of lymphoscintigraphy used at a rural hospital in Australia to identify the correct lymph node for sentinel lymph node biopsy (SLNB) in early-stage breast cancer patients. Methods: A retrospective audit was conducted using imaging and medical record data from 145 eligible patients who underwent preoperative lymphoscintigraphy for SLNB at a single center throughout 2013 and 2014. The lymphoscintigraphy technique included a single periareolar injection with subsequent dynamic and static images as required. Descriptive statistics, sentinel node identification rates, and imaging-surgery concordance rates were generated from the data. Additionally, χ2 analysis was used to examine the relationships between age, previous surgical intervention, and injection site and time until a sentinel node is visualized. The technique and statistical results were directly compared against multiple similar studies in the literature. Results: The sentinel node identification rate was 99.3%, and the imaging-surgery concordance rate was 97.2%. The identification rate was significantly higher than those of similar studies in the literature, and concordance rates were similar across studies. The findings demonstrated that age (P = 0.508) and previous surgical intervention (P = 0.966) did not influence the time it takes to visualize a sentinel node. Injection site did appear to have a statistically significant effect (P = 0.001), with injections in the upper outer quadrant correlating with increased times between injection and visualization. Conclusion: The reported lymphoscintigraphy technique for identifying sentinel lymph nodes for SLNB in early-stage breast cancer patients can be justified as an accurate and effective method that is time-sensitive and has outcomes comparable to those of successful studies in the literature.

我们的目的是研究技术驱动的淋巴显像注射技术在澳大利亚一家农村医院用于识别早期乳腺癌患者前哨淋巴结活检(SLNB)的正确淋巴结的有效性。方法:对2013年至2014年在单一中心接受SLNB术前淋巴显像检查的145例符合条件的患者的影像学和病历数据进行回顾性审计。淋巴显像技术包括单次乳晕周围注射,随后根据需要进行动态和静态图像。描述性统计、前哨淋巴结识别率和影像学-手术一致性率从数据中生成。此外,采用χ2分析检查年龄、既往手术干预、注射部位和前哨淋巴结可见时间之间的关系。技术和统计结果直接与文献中多个类似研究进行比较。结果:前哨淋巴结检出率为99.3%,影像学与手术符合率为97.2%。鉴别率显著高于文献中同类研究,且各研究的符合率相似。结果显示,年龄(P = 0.508)和既往手术干预(P = 0.966)不影响前哨淋巴结可见时间。注射部位似乎有统计学上显著的影响(P = 0.001),注射在上外象限与注射和可视化之间的时间增加相关。结论:所报道的淋巴显像技术鉴别早期乳腺癌前哨淋巴结的SLNB是一种准确有效的方法,具有时间敏感性,其结果可与文献中成功的研究相媲美。
{"title":"Investigating a Technologist-Driven Injection Technique in Lymphoscintigraphy at a Single Rural Center: A Retrospective Audit.","authors":"Skyla Bamforth,&nbsp;Daphne J James,&nbsp;Christopher Skilton,&nbsp;Anthony Smith","doi":"10.2967/jnmt.123.265442","DOIUrl":"https://doi.org/10.2967/jnmt.123.265442","url":null,"abstract":"<p><p>Our aim was to investigate the effectiveness of the technologist-driven injection technique of lymphoscintigraphy used at a rural hospital in Australia to identify the correct lymph node for sentinel lymph node biopsy (SLNB) in early-stage breast cancer patients. <b>Methods:</b> A retrospective audit was conducted using imaging and medical record data from 145 eligible patients who underwent preoperative lymphoscintigraphy for SLNB at a single center throughout 2013 and 2014. The lymphoscintigraphy technique included a single periareolar injection with subsequent dynamic and static images as required. Descriptive statistics, sentinel node identification rates, and imaging-surgery concordance rates were generated from the data. Additionally, χ<sup>2</sup> analysis was used to examine the relationships between age, previous surgical intervention, and injection site and time until a sentinel node is visualized. The technique and statistical results were directly compared against multiple similar studies in the literature. <b>Results:</b> The sentinel node identification rate was 99.3%, and the imaging-surgery concordance rate was 97.2%. The identification rate was significantly higher than those of similar studies in the literature, and concordance rates were similar across studies. The findings demonstrated that age (<i>P</i> = 0.508) and previous surgical intervention (<i>P</i> = 0.966) did not influence the time it takes to visualize a sentinel node. Injection site did appear to have a statistically significant effect (<i>P</i> = 0.001), with injections in the upper outer quadrant correlating with increased times between injection and visualization. <b>Conclusion:</b> The reported lymphoscintigraphy technique for identifying sentinel lymph nodes for SLNB in early-stage breast cancer patients can be justified as an accurate and effective method that is time-sensitive and has outcomes comparable to those of successful studies in the literature.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10168071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
18F-FDG PET/CT Versus 68Ga-PSMA-11 PET/CT in Evaluation of Distant Metastatic Disease in Recurrent Renal Cell Carcinoma. 18F-FDG PET/CT与68Ga-PSMA-11 PET/CT对复发性肾细胞癌远处转移的评价
IF 1.3 Q2 Medicine Pub Date : 2023-09-01 DOI: 10.2967/jnmt.122.264014
Rahul V Parghane, Sandip Basu

Prostate-specific membrane antigen (PSMA) expression has been observed in the neovasculature of various malignancies. We present a case of metastatic renal cell carcinoma (RCC) with comparative 18F-FDG PET/CT and 68Ga-PSMA-11 imaging in which FDG PET/CT failed to detect metastatic thyroid disease and showed less 18F-FDG-concentrating lesions at other sites, whereas 68Ga-PSMA-11 PET/CT identified metastatic thyroid disease and demonstrated intensely 68Ga-PSMA-11-expressing distant metastatic lesions. 68Ga-PSMA-11 PET/CT may be considered a potentially useful imaging technique in RCC to detect metastasis and to guide the choice of specific treatments, such as PSMA-based radionuclide therapy in patients with recurrent metastatic RCC.

前列腺特异性膜抗原(PSMA)在多种恶性肿瘤的新生血管中均有表达。我们报告了一例转移性肾细胞癌(RCC)的18F-FDG PET/CT和68Ga-PSMA-11成像的比较,其中FDG PET/CT未能检测到转移性甲状腺疾病,并且在其他部位显示较少的18F-FDG集中病变,而68Ga-PSMA-11 PET/CT识别了转移性甲状腺疾病,并显示强烈表达68Ga-PSMA-11的远处转移病变。68Ga-PSMA-11 PET/CT可能被认为是RCC检测转移和指导特定治疗选择的潜在有用的成像技术,例如复发转移性RCC患者的psma为基础的放射性核素治疗。
{"title":"<sup>18</sup>F-FDG PET/CT Versus <sup>68</sup>Ga-PSMA-11 PET/CT in Evaluation of Distant Metastatic Disease in Recurrent Renal Cell Carcinoma.","authors":"Rahul V Parghane,&nbsp;Sandip Basu","doi":"10.2967/jnmt.122.264014","DOIUrl":"https://doi.org/10.2967/jnmt.122.264014","url":null,"abstract":"<p><p>Prostate-specific membrane antigen (PSMA) expression has been observed in the neovasculature of various malignancies. We present a case of metastatic renal cell carcinoma (RCC) with comparative <sup>18</sup>F-FDG PET/CT and <sup>68</sup>Ga-PSMA-11 imaging in which FDG PET/CT failed to detect metastatic thyroid disease and showed less <sup>18</sup>F-FDG-concentrating lesions at other sites, whereas <sup>68</sup>Ga-PSMA-11 PET/CT identified metastatic thyroid disease and demonstrated intensely <sup>68</sup>Ga-PSMA-11-expressing distant metastatic lesions. <sup>68</sup>Ga-PSMA-11 PET/CT may be considered a potentially useful imaging technique in RCC to detect metastasis and to guide the choice of specific treatments, such as PSMA-based radionuclide therapy in patients with recurrent metastatic RCC.</p>","PeriodicalId":16548,"journal":{"name":"Journal of nuclear medicine technology","volume":null,"pages":null},"PeriodicalIF":1.3,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10164989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of nuclear medicine technology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1